Ændringer i zonisamidkoncentrationen kan dog forekomme, hvis samtidig behandling med et CYP3A4- inducerende antiepileptikum eller andre lægemidler seponeres, får dosis justeret eller påbegyndes og justering af Zonegrandosis kan blive nødvendig.
These effects are unlikely to be of clinical significance when Zonegran is added to existing therapy; however, changes in zonisamide concentrations may occur if concomitant CYP3A4-inducing anti-epileptic or other medicinal products are withdrawn, dose adjusted or introduced, an adjustment of the Zonegran dose may be required.